EVFM News and Press, Evofem Biosciences Inc. From 06/16/22

Evofem Biosciences (NASDAQ:EVFM) on Thursday said a post analysis of its phase 3 trial evaluating Phexxi showed that the birth control method prevented 99% of pregnancies. The analysis was based on 101 pregnancies in about 1.2K women who used Phexxi over 24.2K acts of intercourse. Phexxi...

Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data PR Newswire Throughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc Analysis...

NEW YORK, NY / ACCESSWIRE / June 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark Roberts, Senior Editor at Traders News ...

The U.S. FDA has extended the shelf life of Evofem's (NASDAQ:EVFM) Phexxi (lactic acid, citric acid, potassium bitartrate) birth control gel from three to four years. When Phexxi was approved in 2020, its shelf life was 30 months. In April 2022, that was extended to three years. Later this ye...

US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years PR Newswire SAN DIEGO , June 2, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. ( Nasdaq: EVFM ) (Evofem) today announced that the U.S. Food and Drug Administration (FDA) ...

Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%. PyroGenesis Canada (PYR) +17%. Evofem Biosciences ...

Gainers: Immix Biopharma (IMMX) +48%. MDxHealth (MDXH) +31%. ClearPoint Neuro (CLPT) +16%. Covetrus (CVET) +14%. Kronos Bio (KRON) +13%. Losers: Evofem Biosciences (EVFM) -58%. Bright Green (BGXX) -26%. Foghorn Therapeutics (FHTX) -19%. N...

Evofem Biosciences (NASDAQ:EVFM) has priced public offering of 22.665M shares of its common stock, 12.835M pre-funded warrants to purchase common stock in lieu of common stock to certain investors and warrants to purchase up to 71M shares of its common stock for gross proceeds of approximatel...

Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering PR Newswire SAN DIEGO , May 20, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten ...

Evofem Biosciences (EVFM) -43% on planned public offering. Ross Stores (ROST) -23% on Q1 results. Bright Green (BGXX) -12%. NeuroMetrix (NURO) -10%. Burlington Stores (BURL) -10%. Novan, Inc. (NOVN) -8%. Upstart Holdings (UPST) -7% Saxena White P.A. files new securiti...